TOKYO, October 24, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the results of non-clinical research on SAIL66, a Chugai’s in-house project under Phase I clinical development for CLDN6 positive solid tumors, have been published in the Journal for ImmunoTherapy of Cancer. The journal is a renowned academic journal in the field of cancer immunotherapy, published by the Society for Immunotherapy of Cancer (SITC) in the United States..

东京，2024年10月24日——中盖制药有限公司（东京：4519）宣布，中盖公司在CLDN6阳性实体瘤第一阶段临床开发的内部项目SAIL66的非临床研究结果已发表在《癌症免疫治疗杂志》上。该杂志是美国癌症免疫治疗学会（SITC）出版的癌症免疫治疗领域的著名学术期刊。。

“SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137” (https://doi.org/10.1136/jitc-2024-009563)

“SAIL66是下一代靶向CLDN6的T细胞参与者，通过与CD3/CD137的双重结合显示出有效的抗肿瘤功效”(https://doi.org/10.1136/jitc-2024-009563)（笑声）

The following findings were demonstrated in this research, which suggest that SAIL66 may be useful as a treatment for CLDN6 positive solid tumors.

这项研究证实了以下发现，这表明SAIL66可能可用作CLDN6阳性实体瘤的治疗方法。

Creation of SAIL66, which is a novel tri-specific T-cell engager* (TCE) for Claudin-6 (CLDN6), CD3, and CD137, applying Dual-Ig® technology, Chugai’s proprietary antibody engineering technology*T-cell engager: A therapeutic agent that exerts anti-tumor effects by bringing T cells, which are immune cells, closer to tumor cells.

SAIL66是一种针对Claudin-6（CLDN6），CD3和CD137的新型三特异性T细胞接合器*（TCE），应用Dual-Ig®技术，Chugai专有的抗体工程技术*T细胞接合器：一种通过使T细胞（免疫细胞）更接近肿瘤细胞来发挥抗肿瘤作用的治疗剂。

SAIL66 binds to CLDN6, which is specifically expressed on tumor tissue, and does not bind to other CLDN family proteins (CLDN3, 4, or 9) with similar amino sequences

SAIL66与在肿瘤组织上特异性表达的CLDN6结合，不与其他具有相似氨基序列的CLDN家族蛋白（CLDN3、4或9）结合

in vitro, SAIL66 was shown to strongly activate T cells and exert cancer cell cytotoxicity by not only triggering CD3 signaling like conventional TCEs, but also by providing CD137 co-stimulation

在体外，SAIL66不仅通过像常规TCE一样触发CD3信号传导，而且通过提供CD137共刺激，显示出强烈激活T细胞并发挥癌细胞的细胞毒性

In experiments using mice, SAIL66 was shown to increase intratumor T-cells and decrease the number of exhausted T cells, leading to enhanced antitumor efficacy compared to conventional TCEs

在使用小鼠的实验中，SAIL66显示出增加肿瘤内T细胞并减少耗尽的T细胞数量，与常规TCE相比，可增强抗肿瘤功效

About SAIL66SAIL66 is an anti-CLDN6/CD3/CD137 trispecific antibody and one of the next-generation T-cell engagers (TCEs) applying Chugai’s proprietary Dual-Ig® technology. Conventional TCEs are designed to guide T cells to the target cancer cells by activating and engaging T cells through its binding to CD3 on T cells.

关于SAIL66SAIL66是一种抗CLDN6/CD3/CD137三特异性抗体，是应用Chugai专有Dual-Ig®技术的下一代T细胞参与者（TCE）之一。常规TCE被设计为通过激活T细胞并通过其与T细胞上的CD3结合来将T细胞引导至靶癌细胞。

Dual-Ig technology is a novel technology providing antibodies with the ability to induce CD137 signaling, a co-stimulating molecule, in addition to CD3 signaling. This property enables to maintain T cell activity, potentially inducing more potent antitumor effects than conventional T-cell engagers.1.

双Ig技术是一种新技术，除了CD3信号传导外，还为抗体提供诱导CD137信号传导（一种共刺激分子）的能力。这种特性能够维持T细胞活性，可能比常规T细胞参与者诱导更有效的抗肿瘤作用。